4 results
To evaluate the safety and efficacy of abicipar (2 mg), compared to 0.5 mg ranibizumab in treatment-naïve patients with neovascular AMD.
The primary objective of this study is to prove noninferiority regarding safety and effectiveness of 30-45 day of DAPT followed by Prasugrel-monotherapy versus standard 12 months of DAPT in patients admitted for STEMI treated by primary PCI.The…
The study aims to evaluate a modified Anti-Platelet Therapy, when associated with low-dose rapamycin DES Firehawk in Acute Myocardial Infarction Patients treated with complete revascularization strategy.. The modified antiplatelet therapy consists…
Primary- Continuation of treatment- SafetySecondairy- Documentation of tolerability